Terms: = Skin cancer AND GRIN2A, Q12879, 2903, ENSG00000183454, NMDAR2A, NR2A
13 results:
1. Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma.
Wong K; Ludwig L; Krijgsman O; Adams DJ; Wood GA; van der Weyden L
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 34296746
[TBL] [Abstract] [Full Text] [Related]
2. Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing.
Kim HJ; Lee M; Lee YB; Yu DS
Acta Derm Venereol; 2021 May; 101(5):adv00458. PubMed ID: 33928395
[TBL] [Abstract] [Full Text] [Related]
3. Somatic synonymous mutations in regulatory elements contribute to the genetic aetiology of melanoma.
Zhang D; Xia J
BMC Med Genomics; 2020 Apr; 13(Suppl 5):43. PubMed ID: 32241263
[TBL] [Abstract] [Full Text] [Related]
4. Genetic and Functional Analysis of grin2a in Tumor Samples.
Prickett TD; Gartner JJ; Samuels Y
Methods Mol Biol; 2017; 1677():93-116. PubMed ID: 28986867
[TBL] [Abstract] [Full Text] [Related]
5. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
Rinner B; Gandolfi G; Meditz K; Frisch MT; Wagner K; Ciarrocchi A; Torricelli F; Koivuniemi R; Niklander J; Liegl-Atzwanger B; Lohberger B; Heitzer E; Ghaffari-Tabrizi-Wizsy N; Zweytick D; Zalaudek I
Sci Rep; 2017 May; 7(1):2098. PubMed ID: 28522871
[TBL] [Abstract] [Full Text] [Related]
6. Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; de Juan Jimenez I; Escutia Muñoz B; Rodríguez Serna M; Alegre de Miquel V; Llavador Ros M; Ballester Sánchez R; Nagore Enguídanos E; Palanca Suela S; Botella Estrada R
Sci Rep; 2017 Mar; 7(1):495. PubMed ID: 28356599
[TBL] [Abstract] [Full Text] [Related]
7. Selected grin2a mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate.
D'mello SA; Joseph WR; Green TN; Leung EY; During MJ; Finlay GJ; Baguley BC; Kalev-Zylinska ML
Cell Calcium; 2016 Dec; 60(6):384-395. PubMed ID: 27659111
[TBL] [Abstract] [Full Text] [Related]
8. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract] [Full Text] [Related]
9. Somatic mutation of grin2a in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.
Prickett TD; Zerlanko BJ; Hill VK; Gartner JJ; Qutob N; Jiang J; Simaan M; Wunderlich J; Gutkind JS; Rosenberg SA; Samuels Y
J Invest Dermatol; 2014 Sep; 134(9):2390-2398. PubMed ID: 24739903
[TBL] [Abstract] [Full Text] [Related]
10. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract] [Full Text] [Related]
11. [Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN
Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
[TBL] [Abstract] [Full Text] [Related]
12. New developments in dermatological oncogenetics.
Kunz M
J Dtsch Dermatol Ges; 2013 Sep; 11(9):831-6. PubMed ID: 23957481
[TBL] [Abstract] [Full Text] [Related]
13. Exome sequencing identifies grin2a as frequently mutated in melanoma.
Wei X; Walia V; Lin JC; Teer JK; Prickett TD; Gartner J; Davis S; ; Stemke-Hale K; Davies MA; Gershenwald JE; Robinson W; Robinson S; Rosenberg SA; Samuels Y
Nat Genet; 2011 May; 43(5):442-6. PubMed ID: 21499247
[TBL] [Abstract] [Full Text] [Related]
